IP Library Granted Patent US 8,796,336
Granted Patent B2
US 8,796,336 · App. 13/188,914 · Granted Aug 5, 2014

Methoxypolyethylene glycol chelate and uses thereof

Inventors: Karl A. Schellenberg (Virginia Beach, VA); Frank A. Lattanzio (Chesapeake, VA); James Shaeffer (Wytheville, VA)
Assignee: Eastern Virginia Medical School
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,336
App. No.
13/188,914
Granted
Aug 5, 2014
Kind
B2
Abstract

The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl radicals or nitric oxides, or heavy metal cations. More particularly, the present invention is concerned with methoxypolyethylene glycol chelate methyl esters that are useful as protectors against tissue damage by penetrating the cell membrane to donate electrons to free radical oxidants and remove heavy metals that may react with peroxides to produce the reactive hydroxyl radical, or remove Ca++ that may be released from organelles. These chelate esters will also have utility in reducing intraocular pressure in glaucoma patients.

Claims (8)

1. A method for preventing retinal cell death resulting from glaucoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a composition comprising a methoxypolyethylene glycol ester of diethylenetriaminepentaacetic acid.

2. The method of claim 1 , wherein the composition is administered topically.

3. The method of claim 1 , wherein the composition is administered intravitreally.

4. The method of claim 1 , wherein the composition further comprises at least one pharmaceutically acceptable carrier or a pharmaceutically acceptable adjuvant.

5. A method of reducing intraocular pressure in a patient comprising administering to the patient a composition comprising an effective amount of a methoxypolyethylene glycol ester of diethylenetriaminepentaacetic acid.

6. The method of claim 5 , wherein the composition is administered topically.

7. The method of claim 5 , wherein the composition is administered intravitreally.

8. The method of claim 5 , wherein the composition further comprises at least one pharmaceutically acceptable carrier or a pharmaceutically acceptable adjuvant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2014
From: SCHELLENBERG, KARL A.; LATTANZIO, FRANK A., JR.; SHAEFFER, JAMES
To: EASTERN VIRGINIA MEDICAL SCHOOL
Reel/Frame 033106/0734 →
Continuity (3)
Continuation 12279521
Provisional Application 60772874 · Feb 14, 2006
Related Publication 20120016030A1 · Jan 19, 2012